All in MPRC 1.7

Last week, the United States Court of Appeals for the Federal Circuit issued an opinion deciding motions to disqualify counsel for Mylan Pharmaceuticals Inc. (“Mylan”) in three appeals pending before the Court: Dr. Falk Pharma GMBH v. Generico, LLC, 2017-2312; Salix Pharma., Inc. v. Mylan Pharma. Inc., 2017-2636, 2018-1320; and Valeant Pharma. Int’l, Inc. v. Mylan Pharma. Inc., 2018-2097 (February 20, 2019).